The latest industry information published by Credence Research, Inc. “Global Chronic Idiopathic Constipation (CIC) Drugs industry – Growth, Share, Opportunities, Competitive Analysis, and Forecast, 2016-2022,” the chronic idiopathic constipation drugs industry was valued at USD 1675.4 Mn in 2015, and is expected to reach USD 2570.8 Mn by 2022, expanding at a CAGR of 6.4% from 2016 to 2022.
Growing awareness and increasing incidence and prevalence of chronic idiopathic constipation – CIC are the major factors driving the CIC drugs industry worldwide. Growth in demand for CIC drugs in Asia Pacific, coupled with the huge gap of unmet needs in the region is expected to serve as a significant opportunity in the global industry during forecast period.
Browse the full report Chronic Idiopathic Constipation (CIC) Drugs Market – Growth, Share, Opportunities, Competitive Analysis, and Forecast, 2016–2022 report athttp://www.credenceresearch.com/report/chronic-idiopathic-constipation-cic-drugs-market
In terms of geographical distribution, North America captures over 40% share of the global industry revenue. US is the largest national industry for CIC drugs due to greater prevalence of lifestyle respective diseases, higher incidence of constipation, higher healthcare spending and rather greater adoption of pharmaceuticals for treating ailments. As per the National Institutes of Health (NIH) CIC affects approximately 63 Mn individuals in the US. On the other hand, growing awareness in the rapidly developing Asian countries such as China and India will create significant growth opportunities in the Asia Pacific industry.
In terms of industry segmentation by drug type, Lubiprostone drugs segment currently dominates the industry. However, the segment due to its relatively lower efficacy, patent loss and growing competition from Linaclotide will lose its dominance in the upcoming future. The Linaclotide drugs industry for CIC treatment is anticipated to grow at a CAGR of 7.7% during 2016 – 2022.
Analyzing the symptoms, constipation is not considered as a disease but a condition, side effect or syndrome. This factor greatly contributes to the lesser visits from patients to address the issue. Thus over 65% of the CIC drugs industry is captured by OTC drugs segment. The OTC industry is expected to continue to dominate the industry at a CAGR of 6.6% during 2016 – 2022.
The CIC drugs industry is currently open for further research and development and thus introduction of novel pharmaceutical solutions. Actavis, Chugai Pharmaceutical, Ferrin International, Synergy Pharmaceuticals and others are among the top payers active in the global chronic idiopathic constipation drugs industry.
Request free Sample : http://www.credenceresearch.com/sample-request/57738
Credence Research is a worldwide industry research and counseling firm that serves driving organizations, governments, non legislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives. Over almost a century, we’ve manufactured a firm extraordinarily prepared to this task.
Name: Chris Smith (Global Sales Manager)
Address: 105 N 1st ST #429, SAN JOSE, CA 95103 US